Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22491754 | 1.00 | RAB9A (0.40) | RAB9APDE5ATSHRGID4ALDH1A1 | |
| SCHEMBL16534907 | 0.85 | SIGMAR1 (0.39) | RAB9ATSHRALDH1A1KMT2ACYP1A2 | |
| SCHEMBL24543429 | 0.84 | ALDH1A1 (0.39) | RAB9ATSHRALDH1A1KMT2ASLC6A3 | |
| SCHEMBL15321005 | 0.84 | RAB9A (0.41) | RAB9ATSHRALDH1A1KMT2ATHRB | |
| SCHEMBL2730679 | 0.84 | TSHR (0.34) | RAB9ATSHRALDH1A1KMT2ATHRB | |
| SCHEMBL297389 | 0.82 | GID4 (0.41) | RAB9ATSHRGID4ALDH1A1KMT2A | |
| SCHEMBL22491760 | 0.82 | GID4 (0.41) | RAB9ATSHRGID4ALDH1A1KMT2A | |
| SCHEMBL297221 | 0.82 | RAB9A (0.34) | RAB9ATSHRGID4KMT2ATAAR1 | |
| SCHEMBL15319401 | 0.77 | PDE5A (0.39) | PDE5ATSHRALDH1A1TAAR1SLC6A3 | |
| SCHEMBL23813107 | 0.75 | PDE5A (0.39) | PDE5AGID4CYP1A2MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352346-B2 | Process for the preparation of 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and the hydrogensulfate salt thereof | ORION CORPORATION (FI) | 2022-06-07 | — | — | US | disclosed |
| EP-3717476-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | Orion Corporation (FI) | 2020-10-07 | — | — | EP | disclosed |
| US-20200308152-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | ORION CORPORATION (FI) | 2020-10-01 | — | — | US | disclosed |
| CN-111630049-A | Process for the preparation of 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and its bisulphate | 奥赖恩公司 | 2020-09-04 | — | — | CN | disclosed |
| EP-2834233-B1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORP (FI) | 2018-04-25 | — | — | EP | disclosed |
| US-9249127-B2 | Alpha2 adrenoceptor agonists | ORION CORPORATION (FI) | 2016-02-02 | — | — | US | disclosed |
| US-9249127-B2 | Alpha2 adrenoceptor agonists | ORION CORPORATION (FI) | 2016-02-02 | — | — | US | disclosed |
| EP-2427444-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2632464-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-04-29 | — | — | EP | disclosed |
| US-9018211-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20150065550-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORPORATION (FI) | 2015-03-05 | — | — | US | disclosed |
| US-20150065550-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORPORATION (FI) | 2015-03-05 | — | — | US | disclosed |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673920-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| EP-2427444-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129379-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065550-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ADRA2A, ADRB2, ADRA2C | RAB9A 1570/4885PDE5A 384/4885TSHR 141/4885 |
| US-20200308152-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | ADRA2A, ADRA2C, ADRB2 | RAB9A 985/4885PDE5A 797/4885TSHR 576/4885 |
| US-11352346-B2 | Process for the preparation of 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and the hydrogensulfate salt thereof | ADRA2A, ADRA2C, ADRB2 | RAB9A 983/4885PDE5A 665/4885TSHR 627/4885 |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | RAB9A 1662/4885PDE5A 1172/4885TSHR 1103/4885 |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | RAB9A 1758/4885PDE5A 1405/4885TSHR 1257/4885 |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | RAB9A 1758/4885PDE5A 1405/4885TSHR 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.